PSY17 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN MEXICO

May 1, 2008, 00:00
10.1016/S1098-3015(10)70498-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)70498-8/fulltext
Title : PSY17 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN MEXICO
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70498-8&doi=10.1016/S1098-3015(10)70498-8
First page :
Section Title :
Open access? : No
Section Order : 217
Categories :
Tags :
Regions :
ViH Article Tags :